37 completed, 8 unknown, 2 terminated. 47 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 47 | Completed 37, Unknown 8, Terminated 2 |
| Phase 2 | 1 | Completed 1 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients Aprepitant 40mg, Placebo - Nausea and Vomiting, Postoperative, Prevention | Phase 3 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 260 | 2026-02-27 | 2026-08-27 |
| Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting Aprepitant Injection, Aprepitant Injection Placebo - Post-operative Nausea and Vomiting (PONV) | Phase 3 | Unknown | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 486 | 2024-10-28 | 2024-08-09 |
| Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC Aprepitant in combination with granisetron and dexamethasone, Granisetron and dexamethasone - Hepatocellular Carcinoma | Phase 3 | Unknown | Guangxi Medical University | 300 | 2024-07-01 | 2024-01-23 |
| Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients Aprepitant Injection - Gynecological Tumor, Ovarian Cancer | Phase 3 | Completed | Sichuan Cancer Hospital and Research Institute | 143 | 2024-05-31 | 2025-12-04 |
| Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea Ibuprofen and Aprepitant - Primary Dysmenorrhea | Phase 3 | Completed | Lahore Medical Research Center, LLP | 40 | 2024-03-15 | 2025-02-21 |
| Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting Aprepitant Injection, Aprepitant Injection Placebo - Postoperative Nausea and Vomiting | Phase 3 | Completed | Qilu Pharmaceutical (Hainan) Co., Ltd. | 518 | 2024-02-02 | 2025-04-23 |
| Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine - Perioperative Optimization | Phase 3 | Completed | Jennifer Holder-Murray | 3395 | 2023-05-15 | 2026-05-28 |
| Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents Ondansetron, Dexamethasone, Aprepitant - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 210 | 2022-04-01 | 2022-07-28 |
| Granisetron Transdermal Patch for Prophylaxis of Delayed CINV Granisetron transdermal patch, Palonosetron, Aprepitant - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 3 | Unknown | Fudan University | 140 | 2021-06-10 | 2021-06-03 |
| Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy Zyprexa® (OLANZapine 5MG), Emend® (Aprepitant) - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | CR-CSSS Champlain-Charles-Le Moyne | 30 | 2019-04-29 | 2020-08-19 |
| Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms Aprepitant 80 mg, Hydroxyzine 25mg, Placebo of Hydroxyzine - Myeloproliferative Disorder, Aquagenic Pruritus | Phase 3 | Completed | University Hospital, Brest | 63 | 2019-04-16 | 2025-12-03 |
| Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy aprepitant, olanzapine 10 mg, olanzapine 5 mg - Antiemetic for Highly Emetogenic Chemotherapy | Phase 3 | Unknown | Mahidol University | 147 | 2019-03-01 | 2019-03-15 |
| Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine - Nausea, Vomiting | Phase 3 | Completed | Rush University Medical Center | 52 | 2017-09-23 | 2024-10-22 |
| "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)" Ondansetron, Dexamethasone, Aprepitant - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | All India Institute of Medical Sciences | 240 | 2017-07-01 | 2019-08-20 |
| Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy Aprepitant, Ondansetron, Metoclopramide - Chemotherapy Induced Vomiting, Acute Myeloid Leukemia | Phase 3 | Unknown | Dr Atul Sharma | 116 | 2016-11-01 | 2017-01-25 |
| Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy Aprepitant, Palonosetron, Dexamethasone - Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Sun Yat-sen University | 248 | 2015-08-04 | 2023-02-08 |
| Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries dexamethasone, Gabapentin, Aprepitant - Postoperative Nausea and Vomiting | Phase 2 / Phase 3 | Completed | Assiut University | 150 | 2015-08-01 | 2016-03-24 |
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting Olanzapine, Aprepitant, Palonosetron - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | First Affiliated Hospital of Harbin Medical University | 120 | 2015-05-01 | 2017-03-30 |
| Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis Aprepitant, Mirtazapine - Breast Cancer | Phase 3 | Completed | Fudan University | 212 | 2014-12-01 | 2022-04-20 |
| Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) - Hematopoietic/Lymphoid Cancer, Nausea and Vomiting | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 401 | 2014-08-20 | 2025-01-28 |
Showing 20 of 47. Sign in to see all of them.
Vomiting (24) · Depressive Disorder, Major (9) · Nausea (6) · Postoperative Nausea and Vomiting (6) · Breast Neoplasms (4) · Breast Neoplasms, Male (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Inflammatory Breast Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1)
Merck Sharp & Dohme LLC (17) · All India Institute of Medical Sciences (2) · Fudan University (2) · S. Maria Hospital, Terni (2) · Alliance for Clinical Trials in Oncology (1) · Assiut University (1) · Azienda Ospedaliera di Perugia (1) · CR-CSSS Champlain-Charles-Le Moyne (1) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Dr Atul Sharma (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · First Affiliated Hospital of Harbin Medical University (1) · Guangxi Medical University (1) · Heidelberg University (1)
United States (7) · China (6) · India (4) · Italy (3) · Canada (2) · Germany (2) · Russia (2) · Bulgaria (1) · Czechia (1) · Egypt (1) · France (1) · Hungary (1) · Pakistan (1) · Poland (1) · Serbia (1)
Fausto Roila, MD (2) · Catherine Prady, Md (1) · Daxin Zhang, MD (1) · Gerlinde Egerer, MD (1) · Hala S Abdel-Ghaffar, MD (1) · Joseph A. Roscoe, PhD (1) · Kathryn Schultz, PharmD (1) · Lawrence Einhorn, M.D. (1) · Le-Qun Li (1) · Leonardo Flenghi, M.D. (1) · Maxim Roy, MD, FRCPC (1) · Nong Yang, MD (1)
PMID 16248986, PMID 16314401, PMID 23062719, PMID 10824073, PMID 11030465, PMID 11497388, PMID 12712486, PMID 12736106, PMID 12784346, PMID 14504060, PMID 14559886, PMID 14635083, PMID 14966097, PMID 15837996, PMID 16766588, PMID 19568773, PMID 19775450, PMID 22024310, PMID 22141732, PMID 22915652, PMID 22915657, PMID 23598819, PMID 24276953, PMID 24323030, PMID 24911369, PMID 25225424, PMID 25743855, PMID 25770814, PMID 26449391, PMID 27410922, PMID 28285236, PMID 29808377, PMID 29893452, PMID 30373688, PMID 30968588, PMID 32036491, PMID 32931400, PMID 32988373, PMID 33122168, PMID 33835174, PMID 34923994, PMID 38154902, PMID 41520166, PMID 8232489, PMID 8996133
2008 (2), 2018 (1), U10CA031946 (1), U10CA037420 (1)